Anzeige
Mehr »
Freitag, 31.10.2025 - Börsentäglich über 12.000 News
Attestation ist die Killer-App - Republic baut sie jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
31.10.25 | 11:59
29,900 Euro
-2,54 % -0,780
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
29,68029,96019:50
29,68029,96019:50

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SaSobi, Inc.: Data presented at ACR Convergence 2025 highlight Sobi's commitment to advancing care across rare and underserved inflammatory conditions1
24.10.Swedish Orphan Biovitrum AB: Sobi showcases new data across rare inflammatory conditions at ACR 2025247STOCKHOLM, Oct. 24, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare disease, will be...
► Artikel lesen
23.10.Swedish Orphan Biovitrum AB reports Q3 results5
21.10.Swedish Orphan Biovitrum AB: Change in the Sobi Board of Directors226STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company today announced that Helena Saxon a member of the Sobi board of Directors, has resigned...
► Artikel lesen
20.10.Sobi Q3 EBIT tops estimates by 14%, lifts full-year guidance after Vonjo hit6
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
20.10.Sobi Q3 Adj. EBITA Rises254BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB reported a third quarter loss of 2.89 billion Swedish kronor compared to profit of 1.46 billion kronor, prior year. Loss per...
► Artikel lesen
20.10.Swedish Orphan Biovitrum AB: Sobi Q3 2025 report: Accelerated growth and portfolio momentum267STOCKHOLM, Oct. 20, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025 Third Quarter 2025 Total...
► Artikel lesen
20.10.Sobi raises 2025 financial forecast after Q3 revenue jumps 21%4
20.10.Sobi Raises FY25 Outlook301STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY, BIOVF, SOBI.ST) or Sobi announced that it raised its outlook for 2025. As part of this update, the company will adjust its financial...
► Artikel lesen
19.10.Swedish Orphan Biovitrum AB: Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report416STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments....
► Artikel lesen
08.10.Swedish Orphan Biovitrum AB: Invitation: Sobi's Q3 2025 report253STOCKHOLM, Oct. 8, 2025 /PRNewswire/ -- Sobi plans to publish its report for the third quarter of 2025 on 23 October 2025 at 08:00 CEST. Investors, analysts, and the media are...
► Artikel lesen
02.10.Kinaxis Inc.: Sobi setzt auf Kinaxis, um den Zugang zu lebensverändernden Behandlungen zu beschleunigen316Durch die Verbindung von KI-gestützter Lieferkettenkoordination und Innovationen im Bereich seltener Krankheiten werden wichtige Therapien für Patienten, die diese benötigen, schneller bereitgestellt...
► Artikel lesen
02.10.Kinaxis Inc: Kinaxis Maestro selected by Swedish Orphan Biovitrum11
02.10.Kinaxis Inc.: Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments291AI-powered supply chain orchestration and rare-disease innovation join forces for faster delivery of critical therapies to patients in need Kinaxis (TSX:KXS), a global leader in end-to-end supply...
► Artikel lesen
30.09.Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi244STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- As per 30 September 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares. All shares are...
► Artikel lesen
23.09.Sobi surpasses Roche in rare disease patient groups' reputation rankings29
22.09.Ionis and Sobi's Tryngolza gains approval in EU for FCS treatment7
19.09.KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs4
19.09.Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome1
19.09.EU approves Ionis and Sobi's FCS treatment Tryngolza4
Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1